Jemperli

Active Ingredient(s): Dostarlimab-gxly
FDA Approved: * April 22, 2021
Pharm Company: * GLAXOSMITHKLINE
Category: Cancer

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer.[1][2][4][5] The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation.[1][2] Additional common side effects reported in the EU include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low lev... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Jemperli 50 mg/ml Intravenous Injection
NDC: 0173-0898
Labeler:
Glaxosmithkline LLC